Computer brain training programs for older adults with mild cognitive impairment
Tests two computer-based brain training programs in older adults with mild cognitive impairment.
Key facts
- Who runs it
- Posit Science Corporation
- Where
- Canada1 site in 1 countryChoose a country to see its sites
- Trial code
- Registry title
- Improving Neurological Health With Acetylcholine Via Neuroplasticity-based Computerized Exercise in Mild Cognitive Impairment
- Status
- Recruiting
- People taking part
- 84 people, planned
- Started
- 25 Sept 2026
- Expected to end
- 31 May 2027
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Computerized speed-based cognitive training
- Computerized executive function cognitive training
- Record updated
- 21 September 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 65 or older with mild cognitive impairment (MCI), a mild drop in memory or thinking. They will use one of two computer-based brain training programs.
- Age
- 65 years or older
- Sex
- All sexes
- Disease stage
- Mild cognitive impairment: MoCA score between 18-26, and a Clinical Dementia Rating (CDR) of 0.5 with a memory score of 0.5 or 1. Daily abilities are still kept.
- Earlier treatment
- If you take dementia medicines such as Donepezil, Memantine or Lecanemab, the dose must be stable for at least 12 weeks. People who already did 10 or more hours of the Posit Science computer training cannot join.
Main reasons for not taking part
- Diagnosed dementia (major neurocognitive disorder)
- Recent suicidal thoughts with a plan or suicide attempts within 2 months, or a depression score above 10 on the GDS-SF
- Pregnant or breastfeeding
- Unable to have MRI/PET scans, for example due to claustrophobia or implanted devices above the waist
- Stroke, moderate to severe brain injury, brain tumor, heart failure, Parkinson's disease, MS or ALS
The registry criteria, word for word
Show all 25 criteriaShow less
Who can take part
- Potential participant must be 65 years or older at the time of study screening
- Potential participant must have MCI as defined by:; Total score between 18-26 inclusive on the Montreal Cognitive Assessment (MoCA); Cognitive concern by participant, informant, or clinician and evidence of preserved functional abilities as defined as a Clinical Dementia Rating (CDR) of 0.5 with a memory score of 0.5 or 1
- Potential participant must have a study partner/informant defined as any acquaintance (e.g., family member, friend, neighbor, clinician) who has regular (at least monthly) interactions (in person or remote) with the participant
- If potential participant reports use of medications typically prescribed for dementia such as, but not limited to, Namenda, Memantine, Namzaric, Donepezil, Aricept, Rivastigmine, Exelon, Razadyne, Galantamine, Reminyl, Aducanumab, Leqembi or Lecanemab, Donanemab, the dose must be stable for at least 12 weeks prior to study enrollment
- Potential participant must demonstrate adequate decisional capacity, in the judgment of the investigator, and capable of to making an informed decision regarding their participation in this research study
- Potential participant must be likely able to complete all study activities and outcome measures in the judgment of the investigator
- Potential participant must have the visual, auditory, and motors capacity to use the computerized intervention in the judgment of the investigator
- Potential participant must be able to communicate in either English or French
Who cannot take part
- Potential participant has previously completed 10 or more hours of the computerized cognitive intervention program manufactured by Posit Science
- Potential participant is participating in a concurrent clinical trial (involving an investigational pharmaceutical, behavioral treatment, medical device or other) that, in the judgment of the investigator, could affect the outcome of this study
- Potential participant is undergoing or plans to undergo surgery requiring anesthesia, chemotherapy, or radiation treatment in the six months following screening (can be rescreened and enrolled later)
- Potential participant has an existing diagnosis of major neurocognitive disorder at screening (DSM-IV)
- Potential participant has a history of large vessel stroke with significant residual motor or cognitive impairment
- Potential participant has a history of moderate to severe traumatic brain injury with residual cognitive symptoms
- Potential participant has a history of brain tumor
- Potential participant has a congestive heart failure diagnosis
- Potential participant has a primary diagnosis of idiopathic Parkinson's disease
- Potential participant has evidence of a non-neurodegenerative neurological disorder that would interfere with the ability to carry out study activities
- Potential participant has has evidence of any other unstable medical conditions that would interfere with the ability to carry out study activities or cause fluctuations in cognition (for example, but not limited to, unstable diabetes, chronic obstructive pulmonary disorder dependent on oxygen)
- Potential participant has any other clinically significant or unstable medical condition (for example, but not limited to, ongoing alcohol dependency or drug abuse, schizophrenia, psychosis) that in the investigator's opinion would interfere with the ability to carry out study activities
- Potential participant who answered 'yes' to question 5 (Active Suicidal Ideation with Specific Plan and Intent) on the C-SSRS or 'yes' to any of the suicide-related behaviors (actual attempt, interrupted attempt, aborted attempt, preparatory act or behavior) on the C-SSRS "Suicidal Behavior" if the ideation or behavior occurred within 2 months from Participant's date of consent (as recommended by the FDA for treatment trials.)
- Potential participant scores >10 on the Geriatric Depression Scale - Short Form (GDS-SF)
- Potential participant is pregnant or breastfeeding
- Potential participant has claustrophobia or implantation with any medical devices above the waist that may concentrate radio frequency fields or have other medical issues that may frustrate participation in MRI/PET imaging procedures
- Potential participant has multiple sclerosis or Amyotrophic lateral sclerosis diagnosis
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This study is a validation study to evaluate efficacy of two neuroplasticity-based, computerized cognitive training programs to improve neurological and neuropsychological health in older adults with mild cognitive impairment (MCI).
The 2 groups in the trial
- Speed TrainingTreatment being tested
Computerized speed-based cognitive training requiring a total maximum of 70 treatment sessions, up to 7 sessions per week, 30 minutes per session.
Treatment: Computerized speed-based cognitive training
- Executive Function TrainingExisting treatment, for comparison
Computerized executive function cognitive training requiring a total maximum of 70 treatment sessions, up to 7 sessions per week, 30 minutes per session.
Treatment: Computerized executive function cognitive training
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Improving Neurological Health With Acetylcholine Via Neuroplasticity-based Computerized Exercise in Mild Cognitive Impairment (INHANCE-MCI)
- Plain-language title
- Computer brain training programs for older adults with mild cognitive impairmentGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 15 November 2026.
- Record updated
- 21 September 2026